# OmniAb share price today (OmniAb, Inc., OABI)

> OmniAb, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. OABI · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/oabi

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $5.18 (+275.4% in a year)
- Revenue (Jun 2026): $13.4 M (+244.2% on a year ago)
- Profit (Jun 2026): −$5.9 M
- ROE: −24%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the OmniAb share price today? OmniAb, Inc.'s share price was $5.18 at the close on 4 November 2026. That is 88.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $5, and at that close it was at the high of that range. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 26 weeks in a row. Over the last 1 year the share price moved +155% while the S&P 500 moved +18%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does OmniAb pay? OmniAb, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is OmniAb on? OmniAb is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is OmniAb profitable? OmniAb, Inc. posted a net loss of $5.9 M in the Jun 2026 quarter. The full FY25 year was a loss of $64.8 M. That loss is 43.7% of the quarter's revenue. The same quarter a year earlier lost $15.9 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does OmniAb make, and is it growing? OmniAb, Inc. reported $13.4 M of revenue in the Jun 2026 quarter, +244.2% on the same quarter a year earlier. That is the 2nd quarter in a row with growth on the year before. Over 4 years it has grown −14.4% a year on average. The last full year, FY25, came in at $18.7 M. The last four reported quarters add to $38.5 M. FY25 revenue was $18.7 M, −29.3% on the year before. Recent pace: the last four quarters grew +105.7% on average, against −14.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +67.0%, against +33.1% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does OmniAb keep? OmniAb, Inc.'s sales have fallen to very little: FY25 revenue was $18.7 M, against $59.1 M in FY22. On sales that small an operating margin is not a useful reading, so this section is left out until sales recover. ## Is OmniAb's profit turning into cash? OmniAb, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $36.5 M of cash, against −$64.8 M of profit. After $565 K of spending on assets, free cash was −$37.0 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does OmniAb's cash go? OmniAb, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $4.1 M on assets over the last 3 years. Averaged over those years that is 7.3% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $4.1 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is OmniAb's P/E ratio, and how does it compare with its own history? OmniAb, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values OmniAb, Inc. at 40.5× its FY25 revenue of $18.7 M. The P/E comes back here once profit turns positive. ## Is the OmniAb business getting better or worse? OmniAb, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does OmniAb earn on its capital? OmniAb, Inc. earned a ROE of −24% in FY25. Its return on capital used (ROIC) is 19.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. The key test, return on capital used minus the cost of capital: −8.3% − 11.4% = −19.7 percentage points. The 11.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does OmniAb have too much debt? OmniAb, Inc. has total debt of $18.9 M against shareholder equity of $260 M as of Jun 2026, so its debt is 0.07× its equity, which is very little. Year by year, that ratio went from 0.06 in FY21 to 0.08 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the OmniAb shareholding pattern? 7.2% of OmniAb, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 6.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is OmniAb from balance-sheet trouble? For OmniAb, Inc., the Z-score is 3.66. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.66 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does OmniAb rank in its industry? There is no score against its industry: OmniAb, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is OmniAb compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to OmniAb in size? OmniAb is the 122nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Ardelyx, Inc., Arbutus Biopharma Corporation and Ginkgo Bioworks Holdings, Inc. Just below it: Wave Life Sciences, XOMA Royalty Corporation and Solid Biosciences Inc. ### Biotechnology companies close in size

1. [Ardelyx, Inc.](https://www.sectoralpha.in/us/stocks/ardx) $827 million
2. [Arbutus Biopharma Corporation](https://www.sectoralpha.in/us/stocks/abus) $803 million
3. [Ginkgo Bioworks Holdings, Inc.](https://www.sectoralpha.in/us/stocks/dna) $785 million
4. OmniAb, Inc. $756 million
5. [Wave Life Sciences Ltd.](https://www.sectoralpha.in/us/stocks/wve) $714 million
6. [XOMA Royalty Corporation](https://www.sectoralpha.in/us/stocks/xoma) $710 million
7. [Solid Biosciences Inc.](https://www.sectoralpha.in/us/stocks/sldb) $699 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [NPK International Inc.](https://www.sectoralpha.in/us/stocks/npki) $759 million · Building Products & Equipment
2. [Legacy Housing Corporation](https://www.sectoralpha.in/us/stocks/legh) $756 million · Residential Construction
3. OmniAb, Inc. $756 million
4. [NerdWallet, Inc.](https://www.sectoralpha.in/us/stocks/nrds) $755 million · Internet Content & Information
5. [Ardmore Shipping Corporation](https://www.sectoralpha.in/us/stocks/asc) $755 million · Marine Shipping

## What else do people ask about OmniAb? ### What were OmniAb's latest quarterly results? OmniAb, Inc. reported revenue of $13.4 M and a net loss of $5.9 M for the Jun 2026 quarter. Earnings per share were −$0.05. The operating margin was −49.5%, 443.7 percentage points higher than a year earlier (as of 4 November 2026). ### What is OmniAb's profit? OmniAb, Inc. earned −$5.9 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was −$64.8 M. The operating margin was −49.5% in the latest quarter (as of 4 November 2026). ### What is OmniAb's market cap? OmniAb, Inc.'s market capitalisation is $756 M at a stock price of $5.18. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is OmniAb performing? OmniAb, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 26 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will OmniAb's stock price go up? This page does not forecast OmniAb, Inc.'s stock price. What it shows instead: the stock price is $5.18. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### What could break the OmniAb story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is OmniAb a stock worth studying right now? What the numbers show: OmniAb, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.